The test is useful to assess ongoing coagulation activation as may occur in thrombosis or DIC. When prothrombin is converted to thrombin, the prothrombin fragment 1.2 is released from prothrombin. The conversion of prothrombin to thrombin is a key event in the coagulation of blood. Prothrombin fragment 1.2 is an activation peptide released from prothrombin during thrombin formation. Activation of prothrombin takes place in the presence of factor Xa, factor Va, calcium ions and a phospholipid suface (platelets). Prothrombin fragment F1+2 may be generated during thrombin formation in two ways. Either prothrombin is cleaved to prethrombin 2 and prothrombin fragment F1+2. Subsequently prethrombin 2 is further cleaved at one position to yield active thrombin. The alternative way of activation is that prothrombin is cleaved to meizothrombin still containing the prothrombin fragment F1+2, and is then processed to thrombin, liberating the prothrombin fragment F1+2. The prothrombin fragment F1+2 may further be cleaved by thrombin to fragments F1 and F2. Prothrombin Fragment 1+2 [F1+2] is an activation peptide that is generated when Prothrombin [Factor II] is converted to Thrombin. Prothrombin is activated to Thrombin [Factor IIa] by a membrane-bound enzyme complex - Prothrombinase and which is assembled through reversible interactions between Factor Xa and Factor Va on membranes containing Phosphatidylserine – a Phospholipid. References: Ota S, Wada H, Abe Y, Yamada E, Sakaguchi A, Nishioka J, Hatada T, Ishikura K, Yamada N, Sudo A, Uchida A, Nobori T. Elevated levels of prothrombin fragment 1 + 2 indicate high risk of thrombosis. Clin Appl Thromb Hemost. 2008 Jul;14(3):279-85. doi: 10.1177/1076029607309176. Epub 2007 Dec 26. PMID: 18160575. Haeberli, A. (1999). Prothrombin fragment F1+2. In: Jespersen, J., Bertina, R.M., Haverkate, F. (eds) Laboratory Techniques in Thrombosis — a Manual. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-4722-4_23

Overview of PTH Antibody as a Biomarker Parathyroid hormone (PTH) antibodies are specialized monoclonal or polyclonal antibodies engineered to specifically bind to parathyroid hormone—a critical regulator of calcium and phosphorus balance in the human body. These antibodies are widely utilized in both biomedical research and clinical diagnostics to detect, measure, and study PTH levels in biological samples. Biological Role of PTH Parathyroid hormone is an 84-amino acid polypeptide secreted by the parathyroid glands. It plays a vital role in calcium and phosphate homeostasis through three main mechanisms: Stimulating bone resorption to release calcium into the bloodstream Enhancing renal calcium reabsorption to reduce urinary calcium loss Promoting activation of vitamin D, which boosts intestinal calcium absorption Disruptions in PTH production or action can lead to: Hypoparathyroidism – low PTH levels, leading to hypocalcemia and hyperphosphatemia Hyperparathyroidism – elevated PTH levels, often resulting in hypercalcemia and hypophosphatemia Applications of PTH Antibodies PTH antibodies are key tools in various laboratory and clinical applications: Immunoassays such as ELISA and cytometric bead arrays for quantifying PTH in serum or plasma Immunohistochemistry for detecting and localizing PTH in tissue samples Disease research, including studies on: Primary and secondary hyperparathyroidism Familial isolated hypoparathyroidism Autoimmune parathyroid conditions These antibodies are available in monoclonal, polyclonal, and recombinant formats, validated for use in multiple assay systems and across different species. PTH Antibody in Disease Context While PTH itself is a widely recognized biomarker for parathyroid function and calcium metabolism, autoantibodies against PTH or parathyroid tissue have been studied for their role in autoimmune hypoparathyroidism. Research findings indicate: Anti-parathyroid antibodies are often detected in patients with idiopathic hypoparathyroidism and certain autoimmune polyendocrine syndromes. These antibodies may target parathyroid-specific antigens or related structures, although their precise diagnostic specificity and pathogenic significance remain under investigation. In some autoimmune cases, antibodies against the calcium-sensing receptor (CaSR)—a regulator of PTH secretion—are also implicated. Summary Table: PTH Antibody Features Feature Details Target Parathyroid hormone (PTH) Applications ELISA, immunohistochemistry, diagnostics, and research Antibody Types Monoclonal, polyclonal, recombinant Molecular Weight (PTH) ~13 kDa Clinical Relevance Parathyroid disorders, calcium/phosphate regulation Disease Associations Hypoparathyroidism, hyperparathyroidism, autoimmune diseases Conclusion PTH antibodies are invaluable tools for the investigation and diagnosis of parathyroid-related disorders. While serum PTH measurement remains central to evaluating parathyroid function, the detection of anti-parathyroid antibodies may offer additional insight, especially in autoimmune conditions like idiopathic hypoparathyroidism. Ongoing research continues to explore their full diagnostic and prognostic potential.